UNIVERSITY OF CALIFORNIA, LOS ANGELES
TAMPA, Texas
Total Received
$1.95B
Total Awards
812
State
Texas
Last Updated
Mar 20, 2026
Yearly Funding Trend
$1.66B24
$268.3M25
$25.2M26
Top 50 Awards to UNIVERSITY OF CALIFORNIA, LOS ANGELES
Largest individual federal awards on record for this recipient, ranked by obligated amount. Data through March 20, 2026.
| Award | Awarding Agency | Program | Place | FY | Obligation |
|---|---|---|---|---|---|
ASST_NON_P30CA016672_075 CANCER CENTER SUPPORT GRANT - MD ANDERSON CANCER CENTER IS A COMPREHENSIVE CANCER CENTER ESTABLISHED WITHIN THE UNIVERSITY OF TEXAS SYSTEM IN 1941. IN 2017, THE INSTITUTION WELCOM… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | HOUSTON, TX-09 | 2024 | $203,145,019 |
CONT_AWD_75R60219C00004_7526_-NONE-_-NONE- HSB117 C 6362 CORD BLOOD CENTER 2 (MD ANDERSON) | Department of Health and Human Services Health Resources and Services Administration | — | HOUSTON, TX-09 | 2024 | $57,937,279 |
ASST_NON_P01CA117969_075 GENETICS AND BIOLOGY OF PANCREATIC DUCTAL ADENOCARCINOMA - OVERALL - ABSTRACT/SUMMARY. THIS MULTI-DISCIPLINARY TEAM FOCUSES ON THE ROLE OF ONCOGENIC KRAS (KRAS*) IN PANCREATIC… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | HOUSTON, TX-09 | 2024 | $38,308,314 |
ASST_NON_P50CA127001_075 SPORE IN BRAIN CANCER - SUMMARY: OVERALL THE OVERARCHING GOAL OF THIS BRAIN CANCER SPORE RENEWAL APPLICATION IS TO REVERSE THE NOTORIOUSLY POOR OUTCOME OF PATIENTS WITH GLIOBLASTO… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | TX-90 | 2024 | $36,567,038 |
ASST_NON_P50CA100632_075 SPORE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER-LEUKEMIA - OVERALL PROJECT SUMMARY LEUKEMIAS AFFECT ABOUT 60,000 INDIVIDUALS, AND CAUSE THE DEATH OF 24,000 INDIVIDUALS ANNU… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | TX-90 | 2025 | $31,405,752 |
ASST_NON_U01DK108328_075 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS, DIABETES AND PANCREATIC CANCER: COORDINATING AND DATA MANAGEMENT CENTER (CSCPDPC-CDMC) - PROJECT SUMMARY A KEY TO THE SUCCESS OF… | Department of Health and Human Services National Institutes of Health | 93.847 DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH | TX-90 | 2024 | $30,393,940 |
ASST_NON_P01CA148600_075 NOVEL CORD BLOOD-DERIVED CELLULAR THERAPIES - OVERALL PROGRAM SUMMARY UMBILICAL CORD BLOOD (CB) IS A VALUABLE SOURCE OF HEMATOPOIETIC PROGENITOR CELLS (HPCS) FOR THE TREATMENT OF… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | TX-90 | 2024 | $24,289,526 |
ASST_NON_P50CA098258_075 MD ANDERSON GYNECOLOGIC SPORE FOR UTERINE CANCERS - OVERALL SUMMARY/ABSTRACT THE OVERALL GOAL OF THE ENDOMETRIAL (UTERINE) CANCER SPORE AT MD ANDERSON CANCER CENTER IS TO CONDUCT… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | HOUSTON, TX-09 | 2024 | $23,853,515 |
ASST_NON_P50CA140388_075 ADMINISTRATIVE SUPPLEMENT TO MD ANDERSON CANCER CENTER PROSTATE CANCER SPORE - PROJECT SUMMARY/ABSTRACT THROUGH THIS APPLICATION, THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | TX-90 | 2024 | $23,262,650 |
ASST_NON_HT94252520003_097 CONVERGENT SCIENCE CANCER CONSORTIUM FOR IMMUNE CELL ENGINEERING | Department of Defense Defense Health Agency | 12.420 MILITARY MEDICAL RESEARCH AND DEVELOPMENT | HOUSTON, TX-09 | 2025 | $19,100,256 |
ASST_NON_UM1CA186688_075 TEXAS EXPERIMENTAL CANCER THERAPEUTICS NETWORK - TEX CTN - PROJECT SUMMARY THE TEXAS EXPERIMENTAL CANCER THERAPEUTIC NETWORK (TEX-CTN) IS COMPRISED OF THE UNIVERSITY OF TEXAS MD… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | HOUSTON, TX-09 | 2024 | $18,916,469 |
ASST_NON_U54CA096300_075 UPR/MDACC: PARTNERSHIP FOR EXCELLENCE IN CANCER RESEARCH (1 OF 2) - THE PARTNERSHIP FOR EXCELLENCE IN CANCER RESEARCH (PARTNERSHIP) BETWEEN THE UNIVERSITY OF PUERTO RICO (UPR) AND… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | TX-90 | 2024 | $17,378,306 |
ASST_NON_U24CA224285_075 MD ANDERSON CANCER IMMUNE MONITORING AND ANALYSIS CENTER MDA-CIMAC - ABSTRACT IMMUNOTHERAPY (IMT) HAS EMERGED AS A PROMISING TREATMENT STRATEGY ACROSS A BROAD SPECTRUM OF HUMAN CA… | Department of Health and Human Services National Institutes of Health | 93.353 21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT | HOUSTON, TX-09 | 2024 | $16,682,682 |
ASST_NON_U01CA086400_075 GREAT LAKES NEW ENGLAND CLINICAL VALIDATION CENTER - THE GREAT LAKES NEW ENGLAND CLINICAL VALIDATION CENTER (GLNE CVC), A CLINICAL VALIDATION CONSORTIUM COMPONENT OF THE EARLY DET… | Department of Health and Human Services National Institutes of Health | 93.394 CANCER DETECTION AND DIAGNOSIS RESEARCH | TX-90 | 2024 | $16,667,828 |
ASST_NON_P40OD010938_075 SQUIRREL MONKEY BREEDING AND RESEARCH RESOURCE - PROJECT SUMMARY: OVERALL COMPONENT THIS APPLICATION IS A COMPETING RENEWAL OF THE “SQUIRREL MONKEY BREEDING AND RESEARCH RESOURCE… | Department of Health and Human Services National Institutes of Health | 93.351 RESEARCH INFRASTRUCTURE PROGRAMS | TX-90 | 2024 | $12,671,152 |
ASST_NON_P40OD024628_075 SPECIFIC PATHOGEN FREE 18 BABOON RESEARCH RESOURCE (SPF18BRR) - PROJECT SUMMARY: OVERALL COMPONENT THIS APPLICATION IS A COMPETING RENEWAL OF THE “SPECIFIC PATHOGEN FREE 18 BABOON… | Department of Health and Human Services National Institutes of Health | 93.351 RESEARCH INFRASTRUCTURE PROGRAMS | HOUSTON, TX-09 | 2024 | $12,534,061 |
ASST_NON_P01AI139449_075 MECHANISMS CONTROLLING DISTINCT GROWTH AND FUNCTIONAL CHARACTERISTICS OF THE PERINATAL AND ADULT THYMUS - SUMMARY THE INTEGRATED HYPOTHESIS OF THIS PROGRAM PROPOSAL IS THAT AGE-A… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | TX-90 | 2024 | $12,031,054 |
ASST_NON_P50CA217674_075 THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER SPORE IN HEPATOCELLULAR CARCINOMA - OVERALL - SUMMARY/ABSTRACT THE OVERALL GOAL OF THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CEN… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | TX-90 | 2024 | $11,270,004 |
ASST_NON_P50CA221707_075 MD ANDERSON CANCER CENTER SPORE IN GASTROINTESTINAL CANCER - OVERALL: SUMMARY/ABSTRACT THE OVERALL GOAL OF THE MD ANDERSON SPORE IN GASTROINTESTINAL CANCER IS TO REDUCE MORTALITY… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | TX-90 | 2025 | $10,942,077 |
ASST_NON_P50CA221703_075 THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER SPORE IN MELANOMA - OVERALL: PROJECT SUMMARY/ABSTRACT MELANOMA IS THE DEADLIEST FORM OF SKIN CANCER, WITH AN INCREASING INCIDENCE… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | TX-90 | 2024 | $10,284,105 |
ASST_NON_UG1CA233329_075 UT MD ANDERSON CANCER CENTER NETWORK LEAD ACADEMIC PARTICIPATING SITE (LAPS) UG1 - PROJECT SUMMARY CLINICAL TRIALS ARE AN INTEGRAL PART OF MD ANDERSON CANCER CENTER’S (MDACC) MISS… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | HOUSTON, TX-09 | 2024 | $10,194,665 |
ASST_NON_U01CA200468_075 CLINICAL VALIDATION CENTER FOR EARLY DETECTION OF PANCREATIC CANCER - EARLY DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) IS AN AREA OF HIGHEST PRIORITY AND AN UNMET NEED F… | Department of Health and Human Services National Institutes of Health | 93.394 CANCER DETECTION AND DIAGNOSIS RESEARCH | TX-90 | 2024 | $10,116,553 |
ASST_NON_UG1CA242609_075 ICAN-PREVENT: MD ANDERSON INTERNATIONAL CANCER PREVENTION CLINICAL TRIAL CONSORTIUM - ABSTRACT CANCER-RELATED DEATH IS THE SECOND MOST COMMON CAUSE OF DEATH IN THE US, AND THE MOS… | Department of Health and Human Services National Institutes of Health | 93.399 CANCER CONTROL | TX-90 | 2024 | $9,807,930 |
ASST_NON_K12CA088084_075 PAUL CALABRESI CLINICAL ONCOLOGY AWARD - ALTHOUGH KNOWLEDGE OF CANCER BIOLOGY IN THE LABORATORY HAS INCREASED EXPONENTIALLY IN RECENT YEARS, PROGRESS IN CANCER TREATMENT IN THE CL… | Department of Health and Human Services National Institutes of Health | 93.398 CANCER RESEARCH MANPOWER | HOUSTON, TX-09 | 2024 | $9,641,818 |
ASST_NON_P01CA193124_075 PROCESSING AND REPAIR OF DNA CROSSLINKS - PROJECT SUMMARY DNA CROSSLINKS, INCLUDING INTERSTRAND CROSSLINKS (ICLS) AND DNA-PROTEIN CROSSLINKS (DPCS) ARE FORMS OF DNA DAMAGE THAT AR… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | HOUSTON, TX-09 | 2024 | $9,348,044 |
ASST_NON_T32CA009599_075 TRAINING OF ACADEMIC SURGICAL ONCOLOGISTS - PROJECT SUMMARY/ABSTRACT WITH THE RAPID PROGRESS IN CANCER BIOLOGY, THERE IS A GREAT NEED TO TRAIN ACADEMIC SURGICAL ONCOLOGISTS WHO CA… | Department of Health and Human Services National Institutes of Health | 93.398 CANCER RESEARCH MANPOWER | TX-90 | 2024 | $8,678,860 |
CONT_AWD_75N97021C00001_7529_-NONE-_-NONE- OPERATION AND MAINTENANCE OF THE CHIMPANZEE CARE CENTER (CCC) | Department of Health and Human Services National Institutes of Health | — | HOUSTON, TX-09 | 2024 | $8,280,891 |
ASST_NON_U01CA200462_075 MD ANDERSON CANCER CENTER EDRN- CLINICAL VALIDATION CENTER FOR EARLY DETECTION OF OVARIAN CANCER WITH A MULTIPLE MARKER ALGORITHM - ABSTRACT: ADVANCES IN CYTOREDUCTIVE SURGERY AND… | Department of Health and Human Services National Institutes of Health | 93.394 CANCER DETECTION AND DIAGNOSIS RESEARCH | TX-90 | 2024 | $8,201,191 |
ASST_NON_P50CA217685_075 U.T. M. D. ANDERSON CANCER CENTER SPORE IN OVARIAN CANCER - OVERALL SUMMARY/ABSTRACT THE OVERALL GOAL OF THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER (MDACC) OVARIAN CANCER S… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | HOUSTON, TX-09 | 2024 | $7,872,334 |
ASST_NON_T32CA101642_075 TRAINING OF ACADEMIC GYNECOLOGIC ONCOLOGISTS | Department of Health and Human Services National Institutes of Health | 93.398 CANCER RESEARCH MANPOWER | HOUSTON, TX-09 | 2024 | $7,671,141 |
ASST_NON_T32CA009666_075 RESEARCH TRAINING IN ACADEMIC MEDICAL ONCOLOGY - PROJECT ABSTRACT THE MD ANDERSON CANCER CENTER (MDACC) T32 RESEARCH TRAINING IN ACADEMIC MEDICAL ONCOLOGY PROGRAM CAPITALIZES ON T… | Department of Health and Human Services National Institutes of Health | 93.398 CANCER RESEARCH MANPOWER | HOUSTON, TX-09 | 2024 | $7,601,068 |
ASST_NON_U54CA224065_075 UNIVERSITY OF TEXAS PDX DEVELOPMENT AND TRIAL CENTER - SUMMARY OUR OVERARCHING GOAL FOR THE UNIVERSITY TEXAS PDX DEVELOPMENT AND TRIAL CENTER (UTPDTC) IS TO OPTIMIZE PERSONALIZED… | Department of Health and Human Services National Institutes of Health | 93.353 21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT | HOUSTON, TX-09 | 2024 | $7,465,372 |
ASST_NON_HT94252420007_097 CLINICAL CONSORTIUM AWARD - COORDINATING CENTER AND CLINICAL RESEARCH SITE EXERCISE THE OPTION YEAR 1 WITH FUNDING. | Department of Defense Defense Health Agency | 12.420 MILITARY MEDICAL RESEARCH AND DEVELOPMENT | HOUSTON, TX-09 | 2024 | $7,419,425 |
ASST_NON_HT94252410991_097 ADVANCING UNDERSTANDING OF METASTATIC BREAST CANCER THROUGH DEVELOPMENT OF A COMPREHENSIVE RESEARCH PLATFORM | Department of Defense Defense Health Agency | 12.420 MILITARY MEDICAL RESEARCH AND DEVELOPMENT | HOUSTON, TX-09 | 2024 | $7,001,734 |
ASST_NON_P50CA281701_075 THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER SPORE IN OVARIAN CANCER - THE OVERALL GOAL OF THE MD ANDERSON CANCER CENTER SPORE IN OVARIAN CANCER IS TO TEST AND TRANSLATE NOVE… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | TX-90 | 2024 | $6,893,291 |
ASST_NON_R01HL124112_075 PROTECTING COLONIC MUCUS TO MITIGATE ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE - PROJECT SUMMARY/ABSTRACT FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES SUCH AS LEUKEMIAS, LYMPHOMAS… | Department of Health and Human Services National Institutes of Health | 93.837 CARDIOVASCULAR DISEASES RESEARCH | TX-90 | 2024 | $6,815,653 |
ASST_NON_R35CA220430_075 MESOCALE AND NANOSCALE TECHNOLOGIES INTEGRATED BY STRUCTURES FOR DNA REPAIR COMPLEXES (MANTIS-DRC) - PROJECT SUMMARY/ABSTRACT CANCER IS LINKED TO ALMOST EVERY HUMAN DNA REPAIR (DR… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | TX-90 | 2024 | $6,779,442 |
ASST_NON_R01CA195524_075 EARLY DETECTION OF HEPATOCELLULAR CARCINOMA - HEPATOCELLULAR CARCINOMA (HCC) IS THE FASTEST GROWING CAUSE OF CANCER-RELATED DEATH IN THE UNITED STATES. TO ADDRESS THE MAGNITUDE OF… | Department of Health and Human Services National Institutes of Health | 93.394 CANCER DETECTION AND DIAGNOSIS RESEARCH | HOUSTON, TX-09 | 2024 | $6,472,433 |
ASST_NON_U54CA274371_075 TUMOR MICROENVIRONMENT CROSSTALK DRIVES EARLY LESIONS IN PANCREATIC CANCER - OVERALL - ABSTRACT PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) IS THE 3RD MOST COMMON CAUSE OF CANCER-RELA… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | NEW YORK, NY-12 | 2024 | $6,296,350 |
ASST_NON_U01CA214263_075 CIRCULATING BIOMARKERS AND IMAGING FOR EARLY DETECTION OF PANCREATIC CANCER - ABSTRACT THE OVERALL GOAL OF THIS RENEWAL APPLICATION IS TO VALIDATE BIOMARKER SIGNATURES ASSOCIATED… | Department of Health and Human Services National Institutes of Health | 93.394 CANCER DETECTION AND DIAGNOSIS RESEARCH | TX-90 | 2024 | $6,264,986 |
ASST_NON_R35HL144805_075 INDUCIBLE EPITHELIAL RESISTANCE: A PROGRAM INVESTIGATING MECHANISMS TO PROTECT AGAINST ACUTE AND CHRONIC COMPLICATIONS OF PNEUMONIA - PROJECT SUMMARY-ABSTRACT PNEUMONIAS CAUSE MIL… | Department of Health and Human Services National Institutes of Health | 93.837 CARDIOVASCULAR DISEASES RESEARCH | TX-90 | 2024 | $6,155,954 |
ASST_NON_W81XWH2020020_097 KIDNEY CANCER CLINICAL TRIALS CONSORTIUM EXTEND THE PERIOD OF PERFORMANCE 1. PER SECTION 711 OF THE NATIONAL DEFENSE AUTHORIZATION ACT (NDAA) 2019, THE US ARMY MEDICAL RESEARCH AC… | Department of Defense Defense Health Agency | 12.420 MILITARY MEDICAL RESEARCH AND DEVELOPMENT | HOUSTON, TX-09 | 2024 | $5,898,796 |
ASST_NON_U54CA280804_075 CENTER FOR TRANSFORMATIVE COMMUNITY-DRIVEN RESEARCH TO PREVENT OBESITY-RELATED CANCER - THE CENTER FOR TRANSFORMATIVE COMMUNITY-DRIVEN RESEARCH TO PREVENT OBESITY-RELATED CANCER (… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | HOUSTON, TX-09 | 2024 | $5,869,013 |
ASST_NON_U54CA274220_075 ACQUIRED RESISTANCE TO THERAPY AND IRON (ARTI) CENTER - OVERALL SUMMARY APPROXIMATELY 50% OF CANCER PATIENTS ARE TREATED WITH RADIATION THERAPY (RT), BUT LOCAL RECURRENCE CAN STIL… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | TX-90 | 2024 | $5,719,340 |
ASST_NON_R01CA047296_075 A PATHWAY OF TUMOR SUPPRESSION - ABSTRACT THE P53 TUMOR SUPPRESSOR IS A DNA DAMAGE/STRESS RESPONSE PROTEIN THAT FUNCTIONS AS A TRANSCRIPTION FACTOR TO REGULATE A LARGE REPERTOIRE… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | HOUSTON, TX-09 | 2024 | $5,598,198 |
ASST_NON_HT94252510745_097 TARGETING GANGLIOSIDE GD2 TO OVERCOME CHEMOTHERAPY RESISTANCE IN TRIPLE-NEGATIVE BREAST CANCER | Department of Defense Defense Health Agency | 12.420 MILITARY MEDICAL RESEARCH AND DEVELOPMENT | HOUSTON, TX-09 | 2025 | $5,471,258 |
ASST_NON_R01CA082577_075 ROLE OF P53 MISSENSE MUTATIONS ON TUMORIGENESIS IN VIVO - PROJECT SUMMARY CANCER IS A COLLECTION OF COMPLEX, HETEROGENEOUS, AND DEVASTATING DISEASES; HOWEVER, ONE COMMON THEME IS… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | HOUSTON, TX-09 | 2024 | $5,432,567 |
ASST_NON_U54CA274321_075 THE HOUSTON CENTER FOR ACQUIRED RESISTANCE RESEARCH (H-CARR) - OVERALL SUMMARY HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) REMAINS A LEADING CAUSE OF CANCER DEATHS WORLDWIDE WI… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | TX-90 | 2024 | $5,352,094 |
ASST_NON_R01DK091310_075 MICRORNA IN DIABETIC NEPHROPATHY - PROJECT SUMMARY/ABSTRACT WE ARE WITNESSING A PARADIGMATIC SHIFT IN THE PRACTICE OF MEDICINE WHEREBY THE CONCEPT OF TARGETING RNAS AS DIAGNOSTIC… | Department of Health and Human Services National Institutes of Health | 93.847 DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH | TX-90 | 2024 | $5,332,780 |
ASST_NON_R01EY019587_075 MEMBRANE PERMEANT PEPTIDES FOR IMAGING CELL FUNCTION - GLAUCOMA IS AN OPTIC NEUROPATHY CHARACTERIZED BY SELECTIVE RETINAL GANGLION CELL (RGC) DEGENERATION WITH ASSOCIATED EXCAVATI… | Department of Health and Human Services National Institutes of Health | 93.867 VISION RESEARCH | TX-90 | 2025 | $5,264,045 |
Top 50 awards shown, ranked by obligated amount. Dates reflect performance period; last-modified dates match USAspending.gov. Complete listings include all transaction history going back to FY2024.
Industries
View All→12345678
BLOOD AND ORGAN BANKS$57.9M
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)$12.7M
VETERINARY SERVICES$8.3M
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY)$6.9M
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY$4.9M
ALL OTHER PROFESSIONAL, SCIENTIFIC, AND TECHNICAL SERVICES$2.0M
ALL OTHER ANIMAL PRODUCTION$862K
RESEARCH AND DEVELOPMENT IN THE SOCIAL SCIENCES AND HUMANITIES$597K
Federal Programs (CFDA)
View All→12345678910
93.397 — CANCER CENTERS SUPPORT GRANTS$414.7M
93.395 — CANCER TREATMENT RESEARCH$287.7M
93.396 — CANCER BIOLOGY RESEARCH$228.1M
93.393 — CANCER CAUSE AND PREVENTION RESEARCH$154.8M
12.420 — MILITARY MEDICAL RESEARCH AND DEVELOPMENT$146.4M
93.394 — CANCER DETECTION AND DIAGNOSIS RESEARCH$129.1M
93.398 — CANCER RESEARCH MANPOWER$69.0M
93.837 — CARDIOVASCULAR DISEASES RESEARCH$48.9M
93.859 — BIOMEDICAL RESEARCH AND RESEARCH TRAINING$47.3M
93.853 — EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS$46.9M
Source: USAspending.gov · All Recipients · Texas